Anti-IL-10 monoclonal antibody therapy can reduce urinary protein and autoreactive IgG levels and inhibit in vitro cellular immune responses of peripheral blood mononuclear cells in SLE patients48. Here, IL10 is linked to systemic lupus erythematosus.